CN1741822A - 利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 - Google Patents
利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 Download PDFInfo
- Publication number
- CN1741822A CN1741822A CN 200380102757 CN200380102757A CN1741822A CN 1741822 A CN1741822 A CN 1741822A CN 200380102757 CN200380102757 CN 200380102757 CN 200380102757 A CN200380102757 A CN 200380102757A CN 1741822 A CN1741822 A CN 1741822A
- Authority
- CN
- China
- Prior art keywords
- cell
- equipment
- physiological fluid
- compartment
- microbubbles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 47
- 239000007788 liquid Substances 0.000 title claims abstract description 26
- 230000003463 hyperproliferative effect Effects 0.000 title claims abstract description 9
- 230000012010 growth Effects 0.000 title claims abstract description 6
- 230000008569 process Effects 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims description 171
- 230000006907 apoptotic process Effects 0.000 claims description 44
- 239000012530 fluid Substances 0.000 claims description 33
- 208000032839 leukemia Diseases 0.000 claims description 21
- 238000012545 processing Methods 0.000 claims description 21
- 239000007789 gas Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 15
- 230000005855 radiation Effects 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000004069 differentiation Effects 0.000 claims description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 6
- 230000005670 electromagnetic radiation Effects 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000002085 persistent effect Effects 0.000 claims description 3
- 210000000441 neoplastic stem cell Anatomy 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 39
- 238000009210 therapy by ultrasound Methods 0.000 description 25
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 22
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000003504 photosensitizing agent Substances 0.000 description 14
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 13
- 230000001640 apoptogenic effect Effects 0.000 description 13
- 102000003952 Caspase 3 Human genes 0.000 description 12
- 108090000397 Caspase 3 Proteins 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 229960003180 glutathione Drugs 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 231100000489 sensitizer Toxicity 0.000 description 9
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102000011727 Caspases Human genes 0.000 description 6
- 108010076667 Caspases Proteins 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
- 208000036626 Mental retardation Diseases 0.000 description 6
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 6
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000003969 glutathione Nutrition 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000003969 blast cell Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960002885 histidine Drugs 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000005393 sonoluminescence Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000010336 energy treatment Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- CCZWSTFVHJPCEM-UHFFFAOYSA-N 2-iodopyridine Chemical compound IC1=CC=CC=N1 CCZWSTFVHJPCEM-UHFFFAOYSA-N 0.000 description 2
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000000191 radiation effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- -1 singlet oxygen free radical Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229940122659 Angiogenesis stimulant Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 description 1
- 208000009527 Refractory anemia Diseases 0.000 description 1
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 1
- 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- XVLXYDXJEKLXHN-UHFFFAOYSA-M dioc6 Chemical compound [I-].O1C2=CC=CC=C2[N+](CCCCCC)=C1C=CC=C1N(CCCCCC)C2=CC=CC=C2O1 XVLXYDXJEKLXHN-UHFFFAOYSA-M 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
无US处理 | 1次US处理 | 3次US处理 | |
无试剂组氨酸甘露醇组氨酸+甘露醇 | 18±615±511±411±2 | 42±824±821±516±3 | 63±536±1130±325±5 |
Claims (42)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42336802P | 2002-11-04 | 2002-11-04 | |
US60/423,368 | 2002-11-04 | ||
US10/358,445 | 2003-02-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101410287A Division CN101125209A (zh) | 2002-11-04 | 2003-11-04 | 利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1741822A true CN1741822A (zh) | 2006-03-01 |
CN100340302C CN100340302C (zh) | 2007-10-03 |
Family
ID=36093913
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101410287A Pending CN101125209A (zh) | 2002-11-04 | 2003-11-04 | 利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 |
CNB2003801027571A Expired - Fee Related CN100340302C (zh) | 2002-11-04 | 2003-11-04 | 利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101410287A Pending CN101125209A (zh) | 2002-11-04 | 2003-11-04 | 利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 |
Country Status (4)
Country | Link |
---|---|
CN (2) | CN101125209A (zh) |
CY (1) | CY1107585T1 (zh) |
PT (1) | PT1562642E (zh) |
SI (1) | SI1562642T1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102600521A (zh) * | 2012-03-19 | 2012-07-25 | 王天欣 | 一种清除血液中病原体的装置和方法 |
CN103732271A (zh) * | 2011-04-12 | 2014-04-16 | 王天欣 | 检测和治疗肿瘤和病毒感染等疾病的方法和装置 |
CN103732271B (zh) * | 2011-04-12 | 2016-11-30 | 王天欣 | 检测和治疗肿瘤和病毒感染等疾病的方法和装置 |
CN113440747A (zh) * | 2021-07-07 | 2021-09-28 | 于波 | 一种超声治疗或评价用装置及系统 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
BE1010407A4 (fr) * | 1996-07-04 | 1998-07-07 | Undatim Ultrasonics | Procede et installation de traitement des eaux. |
CA2335808A1 (en) * | 1998-07-06 | 2000-01-13 | David Kessel | Intracellular sensitizers for sonodynamic therapy |
-
2003
- 2003-11-04 SI SI200330716T patent/SI1562642T1/sl unknown
- 2003-11-04 CN CNA2007101410287A patent/CN101125209A/zh active Pending
- 2003-11-04 PT PT03768598T patent/PT1562642E/pt unknown
- 2003-11-04 CN CNB2003801027571A patent/CN100340302C/zh not_active Expired - Fee Related
-
2007
- 2007-03-20 CY CY20071100386T patent/CY1107585T1/el unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103732271A (zh) * | 2011-04-12 | 2014-04-16 | 王天欣 | 检测和治疗肿瘤和病毒感染等疾病的方法和装置 |
CN103732271B (zh) * | 2011-04-12 | 2016-11-30 | 王天欣 | 检测和治疗肿瘤和病毒感染等疾病的方法和装置 |
CN102600521A (zh) * | 2012-03-19 | 2012-07-25 | 王天欣 | 一种清除血液中病原体的装置和方法 |
CN113440747A (zh) * | 2021-07-07 | 2021-09-28 | 于波 | 一种超声治疗或评价用装置及系统 |
Also Published As
Publication number | Publication date |
---|---|
CY1107585T1 (el) | 2013-03-13 |
CN100340302C (zh) | 2007-10-03 |
SI1562642T1 (sl) | 2007-06-30 |
CN101125209A (zh) | 2008-02-20 |
PT1562642E (pt) | 2007-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1562642B1 (en) | Device and process for treating a liquid medium using ultrasound in preventing the growth of hyperproliferative or infected cells | |
Liu et al. | Can ultrasound enable efficient intracellular uptake of molecules? A retrospective literature review and analysis | |
Carina et al. | Adjuvant biophysical therapies in osteosarcoma | |
Couture et al. | Review of ultrasound mediated drug delivery for cancer treatment: updates from pre-clinical studies | |
Watanabe et al. | Low‐intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin | |
Xiang et al. | Apoptosis of ovarian cancer cells induced by methylene blue-mediated sonodynamic action | |
US20080119421A1 (en) | Process for treating a biological organism | |
Song et al. | Study of the mechanism of sonodynamic therapy in a rat glioma model | |
US20050215764A1 (en) | Biological polymer with differently charged portions | |
US20060147371A1 (en) | Water-soluble compound | |
US20050249667A1 (en) | Process for treating a biological organism | |
Furusawa et al. | Effects of therapeutic ultrasound on the nucleus and genomic DNA | |
Shan et al. | Gold nanorods modified by endogenous protein with light-irradiation enhance bone repair via multiple osteogenic signal pathways | |
CN1376073A (zh) | 通过光化学内化作用在抗原呈递细胞表面上表达抗原的方法 | |
Yumita et al. | Sonodynamically induced antitumor effect of 4‐formyloximethylidene‐3‐hydroxy‐2‐vinyl‐deuterio‐porphynyl (IX)‐6, 7‐diaspartic acid (ATX‐S10) | |
Matsuo et al. | Synergistic inhibition of malignant melanoma proliferation by melphalan combined with ultrasound and microbubbles | |
Mouratidis et al. | Latest advances in the use of therapeutic focused ultrasound in the treatment of pancreatic cancer | |
Hoon Ha et al. | Novel mechanism of gene transfection by low-energy shock wave | |
Wang et al. | Hypocrellin B enhances ultrasound-induced cell death of nasopharyngeal carcinoma cells | |
CN100340302C (zh) | 利用超声波处理液体介质以防止过度增殖或感染细胞生长的设备与方法 | |
CN1876177A (zh) | 含有脂质体细胞因子的生物降解材料的微球血管栓塞剂及其制备和应用 | |
CN1140997A (zh) | 用于治疗增殖性疾病、转移瘤和药物抗性肿瘤的钒酸盐化合物 | |
Hoda | Potential Alternatives to Conventional Cancer Therapeutic Approaches: The Way Forward | |
Yuan et al. | Gamma‐Ray Treatment of Echinococcus Protoscoleces prior to Implantation in Mice Reduces Echinococcosis | |
JPH0847528A (ja) | 人の血液中に存在する細菌又はウイルス等を失活又は低減させる装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ASHLAND LICENSING AND INTELLECTUAL PROPERTY LTD. Free format text: FORMER OWNER: ASHLAND INC. Effective date: 20061110 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20061110 Address after: ohio Applicant after: Ashland Licensing And Intellec Address before: ohio Applicant before: Ashland Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SOLIS TECHNOLOGY CAYMAN COMPANY Free format text: FORMER OWNER: ASHLAND LICENSING AND INTELLEC Effective date: 20150525 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150525 Address after: Schaffhausen Patentee after: Suo Li Cisco skill Cayman company Address before: ohio Patentee before: Ashland Licensing And Intellec |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071003 Termination date: 20171104 |
|
CF01 | Termination of patent right due to non-payment of annual fee |